Bone Marrow Unit, Department of Cytogenetics of The National Center for Bone Marrow Transplantation (CEMO), National Cancer Institute (INCA), Praça da Cruz Vermelha, 23-6º floor, Rio de Janeiro, RJ, Brazil.
Institute of Human Genetics, Jena University, Jena, Germany.
Int J Hematol. 2011 Feb;93(2):232-236. doi: 10.1007/s12185-010-0757-8. Epub 2011 Jan 5.
Classical Burkitt lymphoma/leukemia (BL/L) presenting L3 morphology is found in 1% of childhood ALL. Recently, it has been described that secondary abnormalities could influence the prognosis of these patients. However, little information is available on these cytogenetic abnormalities and their prognostic importance in BL/L. Here, we report four new childhood BL/L cases associated with duplication within 1q or 13q, which exhibited a very unfavorable therapeutic response. We performed both classical and molecular cytogenetic analysis by multicolor chromosome banding of the secondary abnormalities involving the long arms of chromosome 1 or 13. These patients were previously treated with BFM-90 protocol. All of them died during or after the initial treatment. Here, for the first time, the exact breakpoints of the derivative chromosomes involved were determined at the cytogenetic level as 1q21 and 13q33 each.
经典伯基特淋巴瘤/白血病(BL/L)呈现 L3 形态,占儿童急性淋巴细胞白血病(ALL)的 1%。最近,有研究描述继发性异常可能影响这些患者的预后。然而,关于这些细胞遗传学异常及其在 BL/L 中的预后意义的信息很少。在这里,我们报告了四个新的儿童 BL/L 病例,这些病例与 1q 或 13q 内的重复有关,这些病例表现出非常不利的治疗反应。我们通过涉及染色体 1 或 13 长臂的二次异常的多色染色体带型分析,进行了经典和分子细胞遗传学分析。这些患者之前接受了 BFM-90 方案治疗。他们都在初始治疗期间或之后死亡。在这里,我们首次在细胞遗传学水平上确定了涉及的衍生染色体的确切断裂点,分别为 1q21 和 13q33。